Plasma-derived Product Market Market Size, Share, Growth, and Industry Analysis, By Type (By Types (Coagulation Factor,Immune Globulin,Albumin,Others), By Applications (Hospital,Retail Pharmacy,Others) ), By Application (AAA), Regional Insights and Forecast to 2035

Plasma-derived Product Market Overview

Global Plasma-derived Product Market size is projected at USD 30330  million in 2026 and is expected to hit USD 58638.5 million by 2035 with a CAGR of 7.6%.

The Plasma-derived Product Market is a rapidly expanding segment of the global biopharmaceutical industry, driven by increasing therapeutic demand for immunoglobulins, albumin, coagulation factors, and other plasma-based biologics. Plasma-derived products are obtained from human blood plasma through complex fractionation processes and are widely used for treating immune deficiencies, hemophilia, neurological disorders, and critical care conditions. Globally, more than 60 million liters of plasma are collected annually to support plasma fractionation operations. 

The United States remains the largest contributor to the Plasma-derived Product Market ecosystem due to its advanced plasma collection infrastructure and high treatment adoption rates. The country hosts more than 900 plasma collection centers, accounting for over 65% of global plasma supply. Approximately 125,000 patients in the United States are treated annually for primary immunodeficiency disorders using immunoglobulin therapy. Hemophilia affects nearly 30,000 individuals in the country, requiring regular plasma-derived clotting factors. 

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: Over 72% increase in immunoglobulin therapy demand, 64% expansion in plasma collection capacity, 58% growth in autoimmune disease treatments, 49% higher hospital adoption rate, and nearly 67% rise in rare disease diagnosis fueling Plasma-derived Product Market demand globally.
• Major Market Restraint: Around 46% supply limitations in plasma collection, 39% regulatory approval delays, 42% manufacturing complexity challenges, 37% logistics disruptions in plasma transport, and nearly 33% donor availability fluctuations restricting Plasma-derived Product Market expansion.
• Emerging Trends: Nearly 61% expansion in advanced fractionation technologies, 54% rise in recombinant-plasma hybrid therapies, 48% growth in subcutaneous immunoglobulin adoption, 45% increase in home infusion treatments, and 52% digital monitoring adoption across Plasma-derived Product Market supply chains.
• Regional Leadership: North America holds approximately 41% share of plasma collection capacity, Europe contributes nearly 28% production infrastructure, Asia-Pacific accounts for about 23% consumption growth, while Latin America and Middle East collectively represent nearly 8% of the Plasma-derived Product Market demand.
• Competitive Landscape: The top five global manufacturers account for nearly 63% of Plasma-derived Product Market production capacity, while mid-tier biopharmaceutical companies hold around 22% share and emerging biotechnology firms contribute approximately 15% innovation-driven market participation.
• Market Segmentation: Immunoglobulins represent nearly 48% of the Plasma-derived Product Market product segment, albumin contributes about 23%, coagulation factors account for approximately 19%, while other specialty plasma proteins hold nearly 10% market distribution.
• Recent Development: Approximately 44% increase in new plasma collection centers, 38% expansion in global fractionation facilities, 41% rise in plasma-based therapy clinical trials, 36% surge in biologics pipeline approvals, and nearly 47% strategic partnerships strengthening Plasma-derived Product Market supply chains.

Plasma-derived Product Market Latest Trends

The Plasma-derived Product Market is witnessing significant technological transformation driven by improvements in plasma fractionation technologies and advanced biologics processing systems. Plasma-derived immunoglobulins remain the dominant therapy segment, representing nearly half of all plasma protein utilization worldwide. Global healthcare systems report more than 6 million immunoglobulin treatment administrations annually, particularly for neurological and autoimmune conditions. Increasing diagnosis of immune deficiencies, affecting nearly 1 in every 1,200 individuals globally, continues to drive Plasma-derived Product Market expansion. 

Another key trend shaping the Plasma-derived Product Market Trends includes the expansion of plasma collection infrastructure and increased investments in donor recruitment programs. Over 1,200 plasma collection centers currently operate globally, with North America accounting for the majority of donations. Demand for albumin therapies has increased significantly, with hospitals using more than 500 tons of albumin annually in surgical procedures, trauma care, and liver disease management. Subcutaneous immunoglobulin therapy adoption has grown rapidly, representing nearly 35% of new patient treatments due to improved patient convenience and home administration capabilities. 

Plasma-derived Product Market Dynamics

DRIVER

"Increasing Demand for Immunoglobulin and Rare Disease Therapies"

The rising prevalence of immune disorders and rare diseases significantly drives Plasma-derived Product Market Growth across global healthcare systems. More than 400 identified rare immune disorders require plasma-derived immunoglobulin therapy as a primary treatment. Hospitals worldwide report over 70% growth in immunoglobulin usage over the last decade due to expanding neurological and autoimmune indications. Primary immunodeficiency affects approximately 6 million individuals globally, many of whom rely on long-term plasma-derived therapies. Furthermore, hemophilia treatment requires continuous administration of plasma-derived clotting factors, with more than 400,000 diagnosed cases worldwide. 

RESTRAINTS

"Limited Plasma Supply and Complex Manufacturing Process"

One of the major restraints in the Plasma-derived Product Market is the limited availability of plasma donations required for manufacturing biologic therapies. Producing a single gram of immunoglobulin requires plasma from hundreds of donors, highlighting the supply chain complexity. Plasma fractionation facilities require highly specialized infrastructure and stringent regulatory compliance standards, resulting in long production cycles that often exceed 7 to 9 months. Approximately 80% of global plasma supply originates from a limited number of countries, creating supply vulnerability. Additionally, strict donor screening and viral inactivation procedures increase operational complexity. 

OPPORTUNITY

"Expansion of Plasma Collection Infrastructure in Emerging Markets"

Emerging economies present significant opportunities for the Plasma-derived Product Market as healthcare infrastructure and plasma donation programs continue expanding. Countries in Asia-Pacific are rapidly investing in plasma collection centers to reduce dependence on imported plasma-derived biologics. Currently, Asia accounts for nearly 60% of the global population but contributes less than 20% of plasma supply, highlighting strong growth potential. Governments and pharmaceutical manufacturers are launching national plasma donation campaigns to increase domestic plasma availability. Additionally, rising healthcare expenditure and improved diagnostic capabilities are increasing detection rates for rare diseases and immune disorders. 

CHALLENGE

"Regulatory Compliance and Safety Requirements"

Strict regulatory requirements governing plasma collection, testing, and fractionation create substantial challenges for the Plasma-derived Product Market. Plasma-derived therapies require rigorous viral inactivation, pathogen reduction, and quality control protocols to ensure patient safety. Regulatory agencies mandate extensive batch testing and clinical validation processes that can extend product approval timelines significantly. Manufacturing facilities must comply with multiple international safety standards, increasing operational costs by nearly 30% compared with conventional biologic manufacturing. 

Plasma-derived Product Market Segmentation

The Plasma-derived Product Market segmentation is structured by type and application, reflecting the wide clinical usage of plasma proteins in modern healthcare. By type, the market includes coagulation factor, immune globulin, albumin, and other plasma proteins, each serving specific therapeutic needs such as hemophilia treatment, immune deficiency therapy, and critical care management. By application, hospitals represent the largest utilization channel due to extensive inpatient treatment procedures, while retail pharmacies and other healthcare facilities contribute to growing outpatient therapy adoption. 

Download Free Sample to learn more about this report.

BY TYPE

Coagulation Factor: Coagulation factors represent a critical segment in the Plasma-derived Product Market due to their essential role in treating bleeding disorders such as hemophilia A, hemophilia B, and other clotting deficiencies. Globally, hemophilia affects more than 400000 individuals, with nearly 80% of patients diagnosed with hemophilia A requiring factor VIII therapy derived from plasma. Coagulation factor therapies are administered regularly to prevent life-threatening bleeding episodes and surgical complications. In severe cases, patients require multiple infusions every week, significantly increasing demand for plasma-derived clotting proteins. Hospitals and specialized hematology centers administer millions of coagulation factor doses annually to manage bleeding disorders and trauma-related clotting complications. Approximately 70% of patients diagnosed with hemophilia receive long-term prophylactic treatment using coagulation factor concentrates. 

Immune Globulin: Immune globulin products dominate the Plasma-derived Product Market due to their extensive use in treating immune deficiencies, neurological disorders, and autoimmune diseases. Immunoglobulin therapy is derived from pooled human plasma and contains antibodies that help patients with compromised immune systems fight infections. Worldwide, primary immunodeficiency disorders affect approximately 6 million individuals, many of whom rely on lifelong immune globulin therapy. More than 5 million immunoglobulin therapy infusions are performed globally each year. In addition to immune deficiency treatment, immunoglobulin therapy is used in neurological conditions such as chronic inflammatory demyelinating polyneuropathy and Guillain-Barré syndrome, which affect thousands of patients annually. 

Albumin: Albumin is one of the most widely used plasma-derived proteins in clinical medicine, representing a significant segment within the Plasma-derived Product Market Analysis. Human albumin is primarily used for fluid resuscitation, treatment of liver disease complications, burn therapy, and surgical procedures requiring plasma volume expansion. Global medical facilities consume hundreds of tons of albumin annually to support critical care treatments. In liver disease management, albumin therapy is widely used to treat complications such as ascites and hepatorenal syndrome. More than 1.5 million hospital admissions annually involve liver cirrhosis complications requiring albumin infusion therapy. Albumin is also used extensively in trauma care, where rapid plasma volume expansion is required to stabilize patients suffering from severe blood loss. Hospitals represent the primary consumers of albumin therapies, accounting for more than 75% of global albumin usage. 

Others: The “others” segment within the Plasma-derived Product Market includes a range of specialized plasma proteins such as alpha-1 antitrypsin, fibrinogen, and hyperimmune globulins. These products serve niche therapeutic indications and are increasingly gaining attention in rare disease treatment programs. Alpha-1 antitrypsin deficiency affects approximately 1 in 2500 individuals globally and requires plasma-derived replacement therapy to prevent lung tissue damage. Hyperimmune globulins are specialized antibodies produced from plasma donors with high antibody levels against specific pathogens. These therapies are used for post-exposure prophylaxis in diseases such as rabies, hepatitis B, and tetanus. Public health authorities maintain emergency stockpiles of hyperimmune globulins to manage outbreaks and infectious disease exposures. 

BY APPLICATION

Hospital: Hospitals represent the largest application segment within the Plasma-derived Product Market due to the high volume of inpatient treatments requiring plasma-derived biologics. Major hospitals administer immunoglobulins, albumin, and coagulation factors to manage immune deficiencies, trauma cases, neurological disorders, and surgical procedures. Globally, hospitals conduct more than 6 million plasma-derived therapy administrations annually, particularly for autoimmune diseases and bleeding disorders. Emergency departments frequently rely on plasma-derived products to manage severe trauma and hemorrhage cases. Trauma centers report that plasma-derived clotting factor therapies are used in nearly 30% of patients with uncontrolled bleeding. In surgical units, albumin infusions are commonly used to stabilize patients experiencing fluid loss during complex surgical procedures. Hospitals also treat a large number of patients suffering from immune deficiency disorders. 

Retail Pharmacy: Retail pharmacies represent an expanding distribution channel within the Plasma-derived Product Market, particularly for patients receiving long-term outpatient therapy. Many individuals with chronic immune disorders require continuous immunoglobulin treatment that can be administered outside hospital environments. Retail pharmacies supply immunoglobulin products, albumin preparations, and specialty plasma therapies to outpatient clinics and home healthcare providers. Subcutaneous immunoglobulin therapy has significantly increased retail pharmacy distribution volumes due to its suitability for home-based treatment. Patients undergoing long-term therapy often receive monthly supplies of immunoglobulin products through specialty pharmacy services. Approximately 35% of immunoglobulin treatments are now administered outside hospital settings. 

Others: The “others” application segment in the Plasma-derived Product Market includes specialty clinics, home healthcare services, research laboratories, and emergency public health programs. Specialty infusion clinics have expanded significantly in recent years, providing controlled environments for administering immunoglobulin and coagulation factor therapies outside traditional hospital settings. Home healthcare programs represent a growing application area for plasma-derived therapies. Patients with chronic immune disorders often receive subcutaneous immunoglobulin therapy at home under medical supervision. Home infusion therapy programs have increased treatment adherence rates by nearly 40% due to improved convenience and reduced hospital visits. 

Plasma-derived Product Market Regional Outlook

The Plasma-derived Product Market demonstrates strong regional diversification with North America maintaining approximately 41% market share due to its extensive plasma collection infrastructure and advanced healthcare systems. Europe contributes nearly 28% of the global Plasma-derived Product Market share, supported by strong regulatory frameworks and high treatment adoption for rare diseases. Asia-Pacific represents about 23% of global demand as countries expand plasma fractionation capabilities and improve diagnosis of immune disorders. 

Download Free Sample to learn more about this report.

NORTH AMERICA

North America holds the largest share in the Plasma-derived Product Market, accounting for approximately 41% of global demand due to its robust plasma collection network and well-established healthcare infrastructure. The region operates more than 900 plasma donation centers, contributing nearly two-thirds of the global plasma supply used for fractionation processes. The United States plays a dominant role in this regional ecosystem, with millions of plasma donations collected annually to support the production of immunoglobulins, albumin, and coagulation factors. Hospitals and specialty infusion centers across North America administer a large volume of plasma-derived therapies each year. More than 125000 patients in the region receive treatment for primary immunodeficiency disorders, requiring continuous immunoglobulin therapy. Hemophilia treatment programs also contribute significantly to the demand for coagulation factors, with approximately 30000 diagnosed patients receiving clotting factor therapies in the region. Advanced diagnostic technologies have improved the detection of autoimmune and neurological disorders requiring plasma-derived therapies. 

EUROPE

Europe represents nearly 28% of the global Plasma-derived Product Market share and maintains a well-developed healthcare ecosystem that supports advanced biologic therapies. Several European countries have established national plasma donation programs to ensure sustainable supply for fractionation and therapeutic production. More than 250 plasma collection centers operate across Europe, contributing a significant volume of plasma used in manufacturing immunoglobulins and other plasma proteins. The prevalence of rare diseases across Europe has created strong demand for plasma-derived treatments. Approximately 30 million individuals across the region are affected by rare diseases, many of which require immunoglobulin therapy or specialized plasma proteins for treatment. Healthcare systems in countries such as Germany, France, Italy, and Spain have implemented comprehensive treatment programs to support patients suffering from immune disorders and clotting deficiencies. European hospitals administer a large volume of plasma-derived therapies for both inpatient and outpatient care. 

GERMANY Plasma-derived Product Market

Germany represents one of the most advanced healthcare markets within Europe and contributes approximately 6% to the global Plasma-derived Product Market share. The country has a highly developed medical infrastructure with numerous hospitals, specialty clinics, and research institutions actively utilizing plasma-derived therapies. Germany operates more than 40 plasma collection centers that support domestic plasma fractionation and biologic manufacturing operations. The prevalence of immune deficiency disorders and rare genetic diseases has significantly increased demand for plasma-derived therapies across the German healthcare system. Thousands of patients in Germany receive regular immunoglobulin therapy to manage conditions such as primary immunodeficiency and autoimmune neurological disorders. Intravenous immunoglobulin therapy is widely administered in neurology and immunology departments across major hospitals. Germany also maintains a well-structured hemophilia treatment network. 

UNITED KINGDOM Plasma-derived Product Market

The United Kingdom contributes approximately 4% of the global Plasma-derived Product Market share and maintains a strong healthcare system that supports the treatment of immune disorders and rare diseases. The country has implemented structured plasma donation programs to ensure the availability of plasma proteins required for therapeutic manufacturing. Hospitals and specialized treatment centers across the United Kingdom administer thousands of plasma-derived therapy infusions annually. Immunoglobulin therapy represents a significant portion of plasma-derived product usage in the United Kingdom. Approximately 17000 patients receive immunoglobulin therapy for conditions including primary immunodeficiency disorders and autoimmune neurological diseases. Hospitals also use intravenous immunoglobulin therapy to treat inflammatory conditions such as Kawasaki disease and chronic inflammatory demyelinating polyneuropathy. 

ASIA-PACIFIC

Asia-Pacific accounts for approximately 23% of the global Plasma-derived Product Market share and represents one of the fastest expanding regions due to large patient populations and increasing healthcare investments. Countries across the region are rapidly improving plasma collection infrastructure and expanding domestic plasma fractionation capabilities. Several governments have launched national plasma donation campaigns to reduce reliance on imported plasma-derived therapies. The prevalence of immune disorders and rare diseases in Asia-Pacific has created a growing demand for immunoglobulin therapy and other plasma proteins. Millions of individuals across the region suffer from immune deficiencies, neurological disorders, and clotting abnormalities that require plasma-derived treatment. Hospitals and specialty clinics administer increasing volumes of immunoglobulin therapies to manage autoimmune and inflammatory diseases. Asia-Pacific also has a large number of trauma and surgical patients requiring albumin therapy for fluid resuscitation and recovery support. 

JAPAN Plasma-derived Product Market

Japan represents approximately 5% of the global Plasma-derived Product Market share and maintains a highly advanced healthcare system with strong demand for plasma-derived biologics. The country has a well-regulated plasma donation system that supports domestic production of immunoglobulins, albumin, and coagulation factors used in clinical treatments. Hospitals across Japan administer thousands of immunoglobulin therapy treatments annually to manage immune deficiency disorders and autoimmune neurological diseases. Intravenous immunoglobulin therapy is widely used in neurology departments to treat conditions such as Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. Japan also maintains specialized hemophilia treatment centers that provide coagulation factor therapy to patients suffering from clotting disorders. Approximately 5000 individuals in Japan are diagnosed with hemophilia and require regular infusion therapy to prevent bleeding complications and maintain quality of life. 

CHINA Plasma-derived Product Market

China holds approximately 9% share of the global Plasma-derived Product Market and represents one of the fastest developing plasma-derived therapy markets due to its large population and rapidly expanding healthcare system. The country has significantly increased investments in plasma collection centers and fractionation facilities to support domestic production of plasma proteins. Hospitals across China administer increasing volumes of immunoglobulin therapy to treat immune deficiency disorders and autoimmune diseases. Millions of patients are diagnosed annually with conditions requiring plasma-derived therapies, creating strong demand for immunoglobulins and albumin products. China also reports a growing number of trauma and surgical cases requiring albumin therapy for plasma volume expansion. Large hospital networks across the country perform millions of surgical procedures annually, contributing to increasing utilization of plasma-derived biologics. 

MIDDLE EAST & AFRICA

The Middle East & Africa region accounts for approximately 8% of the global Plasma-derived Product Market share and is experiencing gradual growth due to improving healthcare infrastructure and increasing awareness of rare disease treatments. Several countries across the region have begun expanding plasma collection programs to support domestic healthcare needs. Hospitals across the Middle East increasingly rely on immunoglobulin therapy to treat immune deficiency disorders and neurological diseases. Countries such as Saudi Arabia and the United Arab Emirates have established advanced hospital networks capable of administering specialized plasma-derived therapies to patients suffering from autoimmune conditions. Hemophilia treatment programs are also expanding across the region. Thousands of patients in Middle Eastern countries receive regular coagulation factor therapy through national healthcare programs designed to improve treatment accessibility for bleeding disorders. 

List of Key Plasma-derived Product Market Companies

• Takeda
• CSL
• Grifols
• Octapharma
• Kedrion
• LFB Group
• Biotest
• BPL
• RAAS
• CBPO
• Hualan Bio
• Tiantan Bio
• Shuanglin Bio
• Boya Bio
• Yuanda Shuyang
• Weiguang Bio
• Nanyue Bio
• KM Biologics

Top Two Companies with Highest Share

• CSL: Holds approximately 23% share of the global Plasma-derived Product Market supported by more than 300 plasma collection centers and large-scale fractionation capacity supplying immunoglobulins, albumin, and coagulation therapies to over 100 countries.
• Grifols: Accounts for nearly 20% market share globally with extensive plasma collection infrastructure and advanced biologic manufacturing facilities processing millions of liters of plasma annually for immune globulin and albumin production.

Investment Analysis and Opportunities

Investment activity within the Plasma-derived Product Market continues to accelerate as healthcare systems increase focus on rare disease treatments and biologic therapies. Approximately 65% of current investments in the sector are directed toward expanding plasma collection infrastructure and improving fractionation capacity. Global plasma collection facilities have expanded by nearly 44% in the last decade as manufacturers seek to secure long-term plasma supply chains. In addition, around 52% of pharmaceutical companies involved in plasma biologics have increased capital allocation toward manufacturing automation and pathogen reduction technologies. 

Emerging markets present strong investment opportunities for manufacturers seeking to expand plasma protein production capabilities. Asia-Pacific accounts for nearly 60% of the global population but contributes less than 20% of plasma supply, creating a large gap between demand and local production capacity. Governments in several countries have launched plasma donation awareness programs that have increased donor participation by approximately 35%. Additionally, nearly 48% of ongoing biotechnology research initiatives are focused on developing advanced plasma protein purification methods to improve yield efficiency. Strategic partnerships between biotechnology firms and healthcare institutions have increased by nearly 32%, enabling faster development of innovative therapies. 

New Products Development

New product development in the Plasma-derived Product Market is largely focused on expanding the therapeutic applications of immunoglobulins, coagulation factors, and specialized plasma proteins. Approximately 58% of ongoing clinical studies in plasma-derived biologics focus on immune-mediated neurological disorders. Pharmaceutical companies are investing heavily in next-generation immunoglobulin formulations designed for improved absorption and reduced infusion frequency. Subcutaneous immunoglobulin therapies have increased by nearly 45% in clinical adoption due to their suitability for home-based treatment programs. 

Manufacturers are also developing plasma-derived therapies targeting rare genetic disorders and inflammatory diseases. More than 30% of new pipeline therapies involve specialized plasma proteins such as alpha-1 antitrypsin and C1 esterase inhibitors used to treat hereditary angioedema and chronic lung disease conditions. Biopharmaceutical companies have improved purification efficiency by approximately 35% through advanced fractionation processes, enabling higher yields of therapeutic proteins from collected plasma. Additionally, nearly 42% of pharmaceutical development programs focus on improving plasma protein stability for extended shelf life and enhanced treatment accessibility.

Five Recent Developments

• Expansion of plasma collection infrastructure: In 2024, several leading manufacturers expanded plasma collection networks by nearly 18%, increasing donor capacity across North America and Europe. These facilities collectively improved plasma collection volumes by approximately 22%, strengthening supply chains required for manufacturing immunoglobulins, albumin, and coagulation factor therapies.
• Advancement in fractionation technology: Manufacturers introduced advanced plasma fractionation systems that improved protein recovery efficiency by nearly 28%. These technologies enhanced purification of immunoglobulin and albumin products while reducing processing time by approximately 15%, enabling faster availability of critical plasma-derived therapies.
• Growth in immunoglobulin therapy programs: Clinical programs focusing on immunoglobulin therapy expanded by approximately 25% in 2024. Hospitals and specialty clinics reported nearly 30% growth in patient enrollment for treatment of autoimmune neurological diseases and immune deficiency disorders requiring long-term immunoglobulin therapy.
• Strategic partnerships in biologic research: Biotechnology collaborations increased by approximately 21% as pharmaceutical companies partnered with research institutes to develop new plasma-derived therapies for rare diseases. These partnerships supported nearly 33% growth in clinical trials investigating novel plasma protein applications.
• Expansion of manufacturing capacity: Global manufacturers increased plasma fractionation capacity by nearly 19% through facility upgrades and automation technologies. New production lines improved processing efficiency by approximately 26%, allowing higher volumes of plasma-derived biologics to reach hospitals and specialty clinics worldwide.

Report Coverage Of Plasma-derived Product Market

The Plasma-derived Product Market report coverage provides comprehensive insights into the structure, performance, and future outlook of the global plasma-derived biologics industry. The study evaluates market segmentation across major plasma protein categories including immunoglobulins, coagulation factors, albumin, and other specialized plasma proteins. Immunoglobulins represent nearly 48% of total therapeutic utilization, followed by albumin at approximately 23% and coagulation factors contributing close to 19% of global demand. The report highlights the role of plasma collection infrastructure, which has expanded by nearly 40% globally to meet increasing treatment requirements for immune disorders and rare diseases affecting more than 300 million individuals worldwide.

The report also analyzes regional performance across North America, Europe, Asia-Pacific, and the Middle East & Africa, identifying North America as the leading contributor with approximately 41% market share due to its extensive plasma donation network. Europe accounts for nearly 28% share supported by strong regulatory frameworks and advanced healthcare systems. Asia-Pacific represents approximately 23% of global demand as healthcare infrastructure improves and diagnostic capabilities expand. The report further evaluates competitive landscape dynamics, highlighting that the top five manufacturers collectively control nearly 63% of global plasma fractionation capacity.